Javascript must be enabled to continue!
Abstract 2113: Mechanism of action of pixantrone in non-Hodgkin's lymphoma cells
View through CrossRef
Abstract
Background: Pixantrone (PIX), an anthracenedione analog, has shown promising results with reduced cardiotoxicity as compared to structurally similar mitoxantrone and doxorubicin (DOX) in early phase clinical trials in patients with non-Hodgkin’s lymphoma (NHL). The exact mechanisms of action on how PIX induce cell death by targeting DNA replication through intercalating DNA and/or inhibiting Topoisomerase II has not been clearly illustrated.
Methods: A short-term cell proliferation assay (3 days treatment) and a long-term clonogenic assay (cells were treated with the drugs for 24 hours and then allowed to grow into colonies for 10-14 days) were used to assess and compare the effects of PIX and DOX on cell growth in three NHL cell lines, OCI-Ly8, Z138, and Raji. Immunofluorescent assays using γH2AX antibodies, and DAPI staining were used to examine the effect of PIX and DOX on the formation of double-strand breaks and micronuclei.
Results: In the short-term cell proliferation assay, PIX was not as potent as DOX (IC50 values ranging from 22 nM to 2737 nM for PIX and 2.8 nM to 67 nM for DOX). The two drugs were significantly more potent in the long-term clonogenic assay with IC50 values in low nanomolar range (5.1 nM to 82.8 nM) and the difference between PIX and DOX was much smaller. Cells treated with PIX displayed less increases in DNA double-strand breaks compared to those of DOX as quantified by the number of γH2AX positive foci formed in the cells. Furthermore, PIX treatment significantly increased the formation of micronuclei in a drug concentration and time dependent manner.
Conclusions: The findings from the current study indicate that PIX induces DNA damages that impair the chromosomal segregation but do not significantly trigger double-strand breakage checkpoint response. Overall, our results suggest that PIX may exert its antitumor activity via mechanisms that are different from those of DOX.
Citation Format: Serina Ng, Ruben Muñoz, Daniel Von Hoff, Haiyong Han. Mechanism of action of pixantrone in non-Hodgkin's lymphoma cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2113. doi:10.1158/1538-7445.AM2017-2113
American Association for Cancer Research (AACR)
Title: Abstract 2113: Mechanism of action of pixantrone in non-Hodgkin's lymphoma cells
Description:
Abstract
Background: Pixantrone (PIX), an anthracenedione analog, has shown promising results with reduced cardiotoxicity as compared to structurally similar mitoxantrone and doxorubicin (DOX) in early phase clinical trials in patients with non-Hodgkin’s lymphoma (NHL).
The exact mechanisms of action on how PIX induce cell death by targeting DNA replication through intercalating DNA and/or inhibiting Topoisomerase II has not been clearly illustrated.
Methods: A short-term cell proliferation assay (3 days treatment) and a long-term clonogenic assay (cells were treated with the drugs for 24 hours and then allowed to grow into colonies for 10-14 days) were used to assess and compare the effects of PIX and DOX on cell growth in three NHL cell lines, OCI-Ly8, Z138, and Raji.
Immunofluorescent assays using γH2AX antibodies, and DAPI staining were used to examine the effect of PIX and DOX on the formation of double-strand breaks and micronuclei.
Results: In the short-term cell proliferation assay, PIX was not as potent as DOX (IC50 values ranging from 22 nM to 2737 nM for PIX and 2.
8 nM to 67 nM for DOX).
The two drugs were significantly more potent in the long-term clonogenic assay with IC50 values in low nanomolar range (5.
1 nM to 82.
8 nM) and the difference between PIX and DOX was much smaller.
Cells treated with PIX displayed less increases in DNA double-strand breaks compared to those of DOX as quantified by the number of γH2AX positive foci formed in the cells.
Furthermore, PIX treatment significantly increased the formation of micronuclei in a drug concentration and time dependent manner.
Conclusions: The findings from the current study indicate that PIX induces DNA damages that impair the chromosomal segregation but do not significantly trigger double-strand breakage checkpoint response.
Overall, our results suggest that PIX may exert its antitumor activity via mechanisms that are different from those of DOX.
Citation Format: Serina Ng, Ruben Muñoz, Daniel Von Hoff, Haiyong Han.
Mechanism of action of pixantrone in non-Hodgkin's lymphoma cells [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC.
Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2113.
doi:10.
1158/1538-7445.
AM2017-2113.
Related Results
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Abstract
Introduction
Non-Hodgkin lymphoma (NHL) of the thyroid, a rare malignancy linked to autoimmune disorders, is poorly understood in terms of its pathogenesis and treatment o...
Endoscopic and Histopathological Characteristics of Gastrointestinal Lymphoma: A Multicentric Study
Endoscopic and Histopathological Characteristics of Gastrointestinal Lymphoma: A Multicentric Study
Background: Extranodal non-Hodgkin lymphoma (NHL) is more prevalent in the gastrointestinal (GI) tract than in other sites. This study aimed to determine the endoscopic characteris...
Pixantrone is a Safe and Effective Therapeutic Option for Elderly Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma in the Real-World Setting
Pixantrone is a Safe and Effective Therapeutic Option for Elderly Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma in the Real-World Setting
Treatment of Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) remains an unmet need in every day clinical practice. Pixantrone is an approved by European Medicines A...
Non-invasive detection of lymphoma with circulating tumor DNA features and plasma protein marker.
Non-invasive detection of lymphoma with circulating tumor DNA features and plasma protein marker.
e19574 Background: Lymphoma is common cancer worldwide, a large group of lymphoid hematopoietic malignancies including Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) two maj...
Abstract 1189: Revisiting immune exhaustion in Hodgkin’s lymphoma
Abstract 1189: Revisiting immune exhaustion in Hodgkin’s lymphoma
Abstract
Clinical successes with immune check-point blockers have demonstrated the potency of the immune system in controlling cancers, most strikingly in Hodgkin ly...
Isolation and Characterization of a CD34+ Sub-Clone in B-Cell Lymphoma
Isolation and Characterization of a CD34+ Sub-Clone in B-Cell Lymphoma
Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy in the US. Many types remain incurable despite response to initial therapy and achievement of complete remi...
First approach on gastrointestinal lymphoma classification based on histopathology and immunohistochemistry
First approach on gastrointestinal lymphoma classification based on histopathology and immunohistochemistry
Background: The gastrointestinal tract is the most common site of extranodal Non-Hodgkin lymphoma, accounting for 20% to 40% of all extranodal lymphomas. This study aims to accompl...
Bone marrow infiltration by Non-Hodgkin lymphoma: An experience in a tertiary care centre
Bone marrow infiltration by Non-Hodgkin lymphoma: An experience in a tertiary care centre
Objective: To determine the frequency and patterns of bone marrow infiltration in non-Hodgkin lymphoma patients.
Method: The cross-sectional study was conducted at the Armed Forces...

